Does the media prefer ELAN or GPCR?

In the previous week, Elanco Animal Health had 2 more articles in the media than Structure Therapeutics. MarketBeat recorded 8 mentions for Elanco Animal Health and 6 mentions for Structure Therapeutics. Elanco Animal Health's average media sentiment score of 1.37 beat Structure Therapeutics' score of 0.61 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GPCR or AXSM?

In the previous week, Axsome Therapeutics had 7 more articles in the media than Structure Therapeutics. MarketBeat recorded 13 mentions for Axsome Therapeutics and 6 mentions for Structure Therapeutics. Axsome Therapeutics' average media sentiment score of 0.61 beat Structure Therapeutics' score of 0.61 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 3 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, SMMT or GPCR?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A

Is SMMT or GPCR more profitable?

Structure Therapeutics' return on equity of -24.91% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -291.24% -243.07% Structure Therapeutics N/A -24.91% -23.67%

Does the media prefer SMMT or GPCR?

In the previous week, Structure Therapeutics had 1 more articles in the media than Summit Therapeutics. MarketBeat recorded 6 mentions for Structure Therapeutics and 5 mentions for Summit Therapeutics. Structure Therapeutics' average media sentiment score of 0.61 beat Summit Therapeutics' score of 0.42 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Structure Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, GPCR or ABVX?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is GPCR or ABVX more profitable?

Structure Therapeutics' return on equity of -24.91% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Structure Therapeutics N/A -24.91% -23.67% Abivax N/A -99.02% -70.26%

Does the media prefer GPCR or ABVX?

In the previous week, Structure Therapeutics had 1 more articles in the media than Abivax. MarketBeat recorded 6 mentions for Structure Therapeutics and 5 mentions for Abivax. Abivax's average media sentiment score of 1.41 beat Structure Therapeutics' score of 0.61 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend RDY or GPCR?

Structure Therapeutics has a consensus target price of $110.55, indicating a potential upside of 135.30%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Structure Therapeutics 2 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 3 Strong Buy rating(s) 2.89

Does the media refer more to RDY or GPCR?

In the previous week, Structure Therapeutics had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 6 mentions for Structure Therapeutics and 3 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.83 beat Structure Therapeutics' score of 0.61 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Structure Therapeutics (GPCR) Competitors

$46.98 -1.50 (-3.09%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$47.00 +0.02 (+0.04%)

As of 07:35 AM Eastern

Compare

GPCR vs. ELAN, AXSM, SMMT, ABVX, and RDY

Should you buy Structure Therapeutics stock or one of its competitors? MarketBeat compares Structure Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Structure Therapeutics include Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Summit Therapeutics (SMMT), Abivax (ABVX), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

How does Structure Therapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

In the previous week, Elanco Animal Health had 2 more articles in the media than Structure Therapeutics. MarketBeat recorded 8 mentions for Elanco Animal Health and 6 mentions for Structure Therapeutics. Elanco Animal Health's average media sentiment score of 1.37 beat Structure Therapeutics' score of 0.61 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elanco Animal Health presently has a consensus price target of $28.55, indicating a potential upside of 13.39%. Structure Therapeutics has a consensus price target of $110.55, indicating a potential upside of 135.30%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

Structure Therapeutics has lower revenue, but higher earnings than Elanco Animal Health. Structure Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.67	-$232M	-$0.50	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Elanco Animal Health has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.5, indicating that its stock price is 250% less volatile than the broader market.

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Structure Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Structure Therapeutics	N/A	-24.91%	-23.67%

Summary

Elanco Animal Health beats Structure Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Axsome Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Structure Therapeutics currently has a consensus target price of $110.55, indicating a potential upside of 135.30%. Axsome Therapeutics has a consensus target price of $261.48, indicating a potential upside of 17.97%. Given Structure Therapeutics' higher possible upside, research analysts clearly believe Structure Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Structure Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Structure Therapeutics' return on equity of -24.91% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Structure Therapeutics has a beta of -1.5, indicating that its share price is 250% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

In the previous week, Axsome Therapeutics had 7 more articles in the media than Structure Therapeutics. MarketBeat recorded 13 mentions for Axsome Therapeutics and 6 mentions for Structure Therapeutics. Axsome Therapeutics' average media sentiment score of 0.61 beat Structure Therapeutics' score of 0.61 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	3 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Structure Therapeutics has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Structure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Axsome Therapeutics	$638.50M	17.86	-$183.17M	-$3.73	N/A

Summary

Structure Therapeutics beats Axsome Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Structure Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summit Therapeutics has a beta of -1.26, suggesting that its stock price is 226% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.5, suggesting that its stock price is 250% less volatile than the broader market.

Structure Therapeutics' return on equity of -24.91% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Structure Therapeutics	N/A	-24.91%	-23.67%

In the previous week, Structure Therapeutics had 1 more articles in the media than Summit Therapeutics. MarketBeat recorded 6 mentions for Structure Therapeutics and 5 mentions for Summit Therapeutics. Structure Therapeutics' average media sentiment score of 0.61 beat Summit Therapeutics' score of 0.42 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Structure Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics presently has a consensus price target of $26.97, indicating a potential upside of 99.80%. Structure Therapeutics has a consensus price target of $110.55, indicating a potential upside of 135.30%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

Summary

Structure Therapeutics beats Summit Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Structure Therapeutics compare to Abivax?

Structure Therapeutics (NASDAQ:GPCR) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Structure Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Structure Therapeutics' return on equity of -24.91% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Abivax	N/A	-99.02%	-70.26%

In the previous week, Structure Therapeutics had 1 more articles in the media than Abivax. MarketBeat recorded 6 mentions for Structure Therapeutics and 5 mentions for Abivax. Abivax's average media sentiment score of 1.41 beat Structure Therapeutics' score of 0.61 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Structure Therapeutics currently has a consensus price target of $110.55, suggesting a potential upside of 135.30%. Abivax has a consensus price target of $148.54, suggesting a potential upside of 12.96%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Abivax	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Structure Therapeutics has a beta of -1.5, suggesting that its share price is 250% less volatile than the broader market. Comparatively, Abivax has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

Summary

Structure Therapeutics beats Abivax on 10 of the 14 factors compared between the two stocks.

How does Structure Therapeutics compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

In the previous week, Structure Therapeutics had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 6 mentions for Structure Therapeutics and 3 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.83 beat Structure Therapeutics' score of 0.61 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Structure Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
Structure Therapeutics	N/A	-24.91%	-23.67%

Dr. Reddy's Laboratories has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.5, meaning that its stock price is 250% less volatile than the broader market.

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Dr. Reddy's Laboratories has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	2.92	$456M	$0.58	21.58
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Structure Therapeutics has a consensus target price of $110.55, indicating a potential upside of 135.30%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

Summary

Dr. Reddy's Laboratories beats Structure Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Structure Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GPCR vs. The Competition

Export

Metric	Structure Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.45B	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-54.00	20.49	27.07	23.95
Price / Sales	N/A	300.33	515.05	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	1.88	7.92	10.62	6.14
Net Income	-$141.20M	$23.81M	$3.60B	$331.74M
7 Day Performance	-7.14%	-1.09%	-1.26%	-1.82%
1 Month Performance	5.55%	2.56%	1.07%	-1.45%
1 Year Performance	159.13%	42.16%	23.63%	16.32%

Structure Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GPCR Structure Therapeutics	2.0923 of 5 stars	$46.98 -3.1%	$110.55 +135.3%	+144.1%	$3.45B	N/A	N/A	136	News Coverage
ELAN Elanco Animal Health	3.9173 of 5 stars	$25.13 +1.2%	$28.55 +13.6%	+70.3%	$12.40B	$4.72B	N/A	9,400	News Coverage Positive News
AXSM Axsome Therapeutics	3.9684 of 5 stars	$228.28 -2.4%	$259.05 +13.5%	+98.4%	$12.03B	$638.50M	N/A	380	Analyst Forecast
SMMT Summit Therapeutics	3.2465 of 5 stars	$15.30 +0.3%	$26.97 +76.3%	-48.5%	$11.84B	N/A	N/A	110	Upcoming Earnings Analyst Downgrade
ABVX Abivax	2.6756 of 5 stars	$135.98 -2.8%	$148.54 +9.2%	+1,221.6%	$11.16B	N/A	N/A	61	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GPCR) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Structure Therapeutics (GPCR) Competitors

GPCR vs. ELAN, AXSM, SMMT, ABVX, and RDY

How does Structure Therapeutics compare to Elanco Animal Health?

Summary

How does Structure Therapeutics compare to Axsome Therapeutics?

Summary

How does Structure Therapeutics compare to Summit Therapeutics?

Summary

How does Structure Therapeutics compare to Abivax?

Summary

How does Structure Therapeutics compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR vs. The Competition

Structure Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Structure Therapeutics (GPCR) Competitors

GPCR vs. ELAN, AXSM, SMMT, ABVX, and RDY

How does Structure Therapeutics compare to Elanco Animal Health?

Does the media prefer ELAN or GPCR?

Do analysts rate ELAN or GPCR?

Which has higher valuation & earnings, ELAN or GPCR?

Which has more risk & volatility, ELAN or GPCR?

Do insiders & institutionals believe in ELAN or GPCR?

Is ELAN or GPCR more profitable?

Summary

How does Structure Therapeutics compare to Axsome Therapeutics?

Do analysts rate GPCR or AXSM?

Do insiders and institutionals believe in GPCR or AXSM?

Is GPCR or AXSM more profitable?

Which has more volatility & risk, GPCR or AXSM?

Does the media prefer GPCR or AXSM?

Which has preferable earnings and valuation, GPCR or AXSM?

Summary

How does Structure Therapeutics compare to Summit Therapeutics?

Which has preferable valuation & earnings, SMMT or GPCR?

Do institutionals & insiders believe in SMMT or GPCR?

Which has more volatility & risk, SMMT or GPCR?

Is SMMT or GPCR more profitable?

Does the media prefer SMMT or GPCR?

Do analysts prefer SMMT or GPCR?

Summary

How does Structure Therapeutics compare to Abivax?

Do insiders and institutionals have more ownership in GPCR or ABVX?

Which has better valuation & earnings, GPCR or ABVX?

Is GPCR or ABVX more profitable?

Does the media prefer GPCR or ABVX?

Do analysts prefer GPCR or ABVX?

Which has more volatility and risk, GPCR or ABVX?

Summary

How does Structure Therapeutics compare to Dr. Reddy's Laboratories?

Does the media refer more to RDY or GPCR?

Is RDY or GPCR more profitable?

Which has more risk and volatility, RDY or GPCR?

Do insiders & institutionals have more ownership in RDY or GPCR?

Which has better earnings & valuation, RDY or GPCR?

Do analysts recommend RDY or GPCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR vs. The Competition

Structure Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools